Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic, Inc. - Common Stock (NQ:IMUX)

0.7714 -0.0086 (-1.10%)
Streaming Delayed Price Updated: 1:42 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunic, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,... 
Via TheNewswire.com
Topics Intellectual Property
IMUX Stock Earnings: Immunic Misses EPS for Q1 2024
IMUX stock results show that Immunic missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal 
Via News Direct
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in... 
Via TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
--News Direct-- 
Via News Direct
Immunic's Earnings Outlook
 
Via Benzinga
Immunic: Q3 Earnings Insights
 
Via Benzinga
A Preview Of Immunic's Earnings
 
Via Benzinga
Immunic "super excited" about latest PMS trial data
--News Direct-- 
Via News Direct
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,... 
Via TheNewswire.com
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
What's Going On With Immunic Stock?
Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! 
Via InvestorPlace
Immunic Inc eyeing "big step" for multiple sclerosis patients
--News Direct-- 
Via News Direct
Immunic CSO hails "great" progress with MS program
--News Direct-- 
Via News Direct
Immunic CSO hails "great" progress with MS program
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some... 
Via TheNewswire.com
Immunic "super excited" about latest PMS trial data
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial... 
Via TheNewswire.com
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Multiple Sclerosis Impacts 1M People In US - Immunic Reveals 'Positive' Data From Nerve Disorder Candidate
Immunic Inc (NASDAQ: IMUX) announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with  
Via Benzinga
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
--News Direct-- 
Via News Direct
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial... 
Via TheNewswire.com
Immunic CEO says Q2 results "couldn't be better"
--News Direct-- 
Via News Direct
Immunic CEO says Q2 results "couldn't be better"
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and... 
Via TheNewswire.com
Immunic Inc eyeing "big step" for multiple sclerosis patients
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS)... 
Via TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.